Factor V Leiden mutation is associated with improved 30-day survival in patients with acute respiratory distress syndrome

被引:18
作者
Adamzik, Michael [1 ,2 ]
Frey, Ulrich H. [1 ,2 ]
Riemann, Kathrin [2 ]
Sixt, Stephan [1 ]
Lehmann, Nils [3 ]
Siffert, Winfried [2 ]
Peters, Juergen [1 ]
机构
[1] Univ Klinikum Essen, Univ Duisburg Essen, Klin Anasthesiol & Intens Med, Essen, Germany
[2] Univ Klinikum Essen, Univ Duisburg Essen, Inst Pharmakogenet, Essen, Germany
[3] Univ Klinikum Essen, Univ Duisburg Essen, Inst Med Informat Biometrie & Epidemiol, Essen, Germany
关键词
acute respiratory distress syndrome; protein C; thrombin; factor V Leiden;
D O I
10.1097/CCM.0b013e318174373d
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objective: Activation of coagulation and inflammation are parts of the innate host response to infection that may contribute to organ dysfunction and death when control of these systems is compromised. Thus, functional single nucleotide polymorphisms within candidate genes of the inflammation and coagulation cascade are possible factors which may influence severity and/or mortality in acute respiratory distress syndrome. The aim of this study was to investigate whether the factor V Leiden mutation (Arg506Gln) is associated with altered severity and/or mortality in acute respiratory distress syndrome. Design: Retrospective cohort, genetic association study. Setting. Tertiary care intensive care unit. Patients., Adults (white Germans) with acute respiratory distress syndrome (n = 106). Interventions: Genotyping for the factor V Leiden mutation. Measurements, and Main Results: Using Kaplan-Meier estimates to compare outcome, 30-day survival was significantly associated with the factor V Leiden mutation (p =.049). Thirty-day survival rates were 100% for Arg/Gln (n = 7) genotypes but only 58% for Arg/Arg (n = 99) genotypes, respectively. Conclusion: We show for the first time that a heterozygous factor V Leiden genotype is associated with improved 30-day survival in patients with acute respiratory distress syndrome.
引用
收藏
页码:1776 / 1779
页数:4
相关论文
共 31 条
[1]   Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis -: A randomized controlled trial [J].
Abraham, E ;
Reinhart, K ;
Opal, S ;
Demeyer, I ;
Doig, C ;
Rodriguez, AL ;
Beale, R ;
Svoboda, P ;
Laterre, PF ;
Simon, S ;
Light, B ;
Spapen, H ;
Stone, J ;
Seibert, A ;
Peckelsen, C ;
De Deyne, C ;
Postier, R ;
Pettilä, V ;
Sprung, CL ;
Artigas, A ;
Percell, SR ;
Shu, V ;
Zwingelstein, C ;
Tobias, J ;
Poole, L ;
Stolzenbach, JC ;
Creasey, AA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (02) :238-247
[2]   ACE I/D but not AGT (-6)A/G polymorphism is a risk factor for mortality in ARDS [J].
Adamzik, M. ;
Frey, U. ;
Sixt, S. ;
Knemeyer, L. ;
Beiderlinden, M. ;
Peters, J. ;
Siffert, W. .
EUROPEAN RESPIRATORY JOURNAL, 2007, 29 (03) :482-488
[3]   Sepsis and coagulation [J].
Aird, WC .
CRITICAL CARE CLINICS, 2005, 21 (03) :417-+
[4]   Natural anticoagulant inhibitors: activated protein C [J].
Aird, WC .
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2004, 17 (01) :161-182
[5]   The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent [J].
Bajzar, L ;
Nesheim, ME ;
Tracy, PB .
BLOOD, 1996, 88 (06) :2093-2100
[6]   REPORT OF THE AMERICAN-EUROPEAN CONSENSUS CONFERENCE ON ACUTE RESPIRATORY-DISTRESS SYNDROME - DEFINITIONS, MECHANISMS, RELEVANT OUTCOMES, AND CLINICAL-TRIAL COORDINATION [J].
BERNARD, GR ;
ARTIGAS, A ;
BRIGHAM, KL ;
CARLET, J ;
FALKE, K ;
HUDSON, L ;
LAMY, M ;
LEGALL, JR ;
MORRIS, A ;
SPRAGG, R ;
Cochin, B ;
Lanken, PN ;
Leeper, KV ;
Marini, J ;
Murray, JF ;
Oppenheimer, L ;
Pesenti, A ;
Reid, L ;
Rinaldo, J ;
Villar, J ;
van Asbeck, BS ;
Dhainaut, JF ;
Mancebo, J ;
Matthay, M ;
Meyrick, B ;
Payen, D ;
Perret, C ;
Fowler, AA ;
Schaller, MD ;
Hudson, LD ;
Hyers, T ;
Knaus, W ;
Matthay, R ;
Pinsky, M ;
Bone, RC ;
Bosken, C ;
Johanson, WG ;
Lewandowski, K ;
Repine, J ;
Rodriguez-Roisin, R ;
Roussos, C ;
Antonelli, MA ;
Beloucif, S ;
Bihari, D ;
Burchardi, H ;
LeMaire, F ;
Montravers, P ;
Petty, TL ;
Robotham, J ;
Zapol, W .
JOURNAL OF CRITICAL CARE, 1994, 9 (01) :72-81
[7]   Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].
Bernard, GR ;
Vincent, JL ;
Laterre, P ;
LaRosa, SP ;
Dhainaut, JF ;
Lopez-Rodriguez, A ;
Steingrub, JS ;
Garber, GE ;
Helterbrand, JD ;
Ely, EW ;
Fisher, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709
[8]   MUTATION IN BLOOD-COAGULATION FACTOR-V ASSOCIATED WITH RESISTANCE TO ACTIVATED PROTEIN-C [J].
BERTINA, RM ;
KOELEMAN, BPC ;
KOSTER, T ;
ROSENDAAL, FR ;
DIRVEN, RJ ;
DERONDE, H ;
VANDERVELDEN, PA ;
REITSMA, PH .
NATURE, 1994, 369 (6475) :64-67
[9]  
Boehme MWJ, 1996, IMMUNOLOGY, V87, P134
[10]   DEFINITIONS FOR SEPSIS AND ORGAN FAILURE [J].
BONE, RC ;
SPRUNG, CL ;
SIBBALD, WJ .
CRITICAL CARE MEDICINE, 1992, 20 (06) :724-726